VRCI Verici Dx Plc

TIDMVRCI

RNS Number : 5717B

Verici Dx PLC

05 June 2023

Verici Dx plc

("Verici Dx" or the "Company")

Proposed US pricing for Tutivia(TM)

Medicare proposed gapfill median rate of $2,650 per test

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a gapfill median rate of $2,650 has been proposed for Tutivia(TM) for kidney transplant rejection by the Centers for Medicare & Medicaid Services ("CMS").

Medicare is a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish payment rates for clinical laboratory tests under the Clinical Laboratory Fee Schedule ("CLFS") when no comparable test already exists on the CLFS.

The proposed rate was supported by the majority of Medicare Administrative Contractor ("MAC") localities, including Palmetto GBA, the MAC that will process future Medicare claims submitted for tests performed in Verici's Tennessee laboratory. This proposed rate is currently open for public comment before it is finalised later this year. Following finalisation, the price in the CLFS is valid for a period of three years from 1 January 2024, after which it is subject to further review.

Sara Barrington, Chief Executive Officer of Verici Dx, commented: "This is another important milestone in our commercial strategy, and we are pleased the majority of MAC localities have proposed pricing for our Tutivia(TM) tests consistent with the resources required to develop and perform these tests. I look forward to the pricing being finalised later this year and securing reimbursement coverage in due course."

Enquiries:

 
Verici Dx                                                        www.v ericidx .com 
Sara Barrington, CEO                                                Via Walbrook PR 
Julian Baines, Chairman 
 
Singer Capital Markets (Nominated                             Tel: +44 20 7496 3000 
 Adviser & Broker) 
Aubrey Powell / Sam Butcher 
 
Walbrook PR Limited                Tel: +44 20 7933 8780 or vericidx@walbrookpr.com 
Paul McManus / Stephanie Cuthbert                  Mob: +44 7980 541 893 / +44 7796 
 /                                                                        794 663 / 
 Sam Allen                                                            07502 558 258 
 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Verici Dx's two lead products are Tutivia(TM), a post-transplant test focused upon acute cellular rejection, including sub-clinical rejection and Clarava(TM), a pre-transplant prognosis test for the risk of early acute rejection. These products seek to measure how a patient is likely to respond, and is responding, to a kidney transplant. These products are underpinned by extensive patented and published scientific research from the leading Mount Sinai Medical Center, for which the Company holds an exclusive worldwide licence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCXZLFBXQLFBBX

(END) Dow Jones Newswires

June 05, 2023 02:00 ET (06:00 GMT)

Verici Dx (LSE:VRCI)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Verici Dx (LSE:VRCI)
Historical Stock Chart
Von Dez 2023 bis Dez 2024